Avantor, BlueWhale Partner Bio to Accelerate CAR-T Cell Therapy Manufacturing

Avantor Inc. (NYSE:AVTR) is one of the best large cap stocks to buy under $20. On October 15, Avantor announced a partnership with BlueWhale Bio, which is a commercial-stage company that transforms immune cell therapy manufacturing. The collaboration addresses the unmet needs in CAR-T production by streamlining manufacturing, reducing variability, and shortening the time it takes to get therapies to patients.

The core of the partnership combines Avantor’s expertise in bioprocessing and custom ancillary-reagent manufacturing capabilities with BlueWhale Bio’s proprietary Synecta cell-derived nanoparticle/CDNP platform, which is designed to mimic natural T-cell stimulation. The acceleration is crucial to help CAR-T developers reduce the cell expansion time during manufacturing.

The partnership combines BlueWhale Bio’s novel Synecta platform with Avantor’s industrial-strength execution to accelerate the journey from discovery to delivery. Data from BlueWhale Bio’s preclinical and clinical programs indicate that the technology can lead to earlier cell division, higher cell yields, and fewer process interventions, which shows potential for reducing the overall CAR-T process time and minimizing cell stress during manufacturing.

Avantor Inc. (NYSE:AVTR) provides mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

While we acknowledge the potential of AVTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.